CRA analyzed market definition in antitrust litigation concerning a product in the non-opioid pain category. In defining the relevant antitrust market, our work accounted for indicators of competition among branded pharmaceutical products, including market positioning, factors driving physician choice, development of new approved indications, and competition for formulary listing.
CRA expands its Antitrust Practice with addition of M&A specialist and litigation expert
“I am pleased to welcome Hitesh back to CRA,” said Paul Maleh, President and Chief Executive Officer of Charles River Associates. “He specializes in antitrust...